Net proceeds of the offering will be used to support completion of Hana's pivotal Phase II clinical trial of Marqibo in adult patients with Philadelphia chromosome negative acute lymphoblastic leukemia and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment.
The proceeds will also support Hana's planned regulatory activities related to Marqibo including new drug application preparation and submission.
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index